Back to today’s briefing

Story perspectives

Study Reveals GLP-1 Drugs Slash Dementia Risk in Diabetes

7/24/2025

27 5

Summary

Story summary

A groundbreaking study in BMJ Open Diabetes Research & Care reveals that GLP-1 receptor agonists could significantly lower dementia risk in type 2 diabetes patients, outperforming metformin. With a 10% reduction in dementia risk and a 12% decrease in Alzheimer’s risk, this research calls for a reevaluation of current treatment guidelines.

1 of 1

Story summary

A groundbreaking study in BMJ Open Diabetes Research & Care reveals that GLP-1 receptor agonists could significantly lower dementia risk in type 2 diabetes patients, outperforming metformin. With a 10% reduction in dementia risk and a 12% decrease in Alzheimer’s risk, this research calls for a reevaluation of current treatment guidelines.